End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.15 EGP | -0.16% | -0.81% | +30.30% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.30% | 187M | B- | ||
-18.39% | 17.03B | B+ | ||
+4.50% | 12.61B | B | ||
+4.48% | 11.73B | B+ | ||
+2.50% | 10.17B | B+ | ||
-2.68% | 7.81B | A- | ||
+22.36% | 7.25B | D | ||
+3.46% | 6.66B | B- | ||
+47.50% | 4.51B | - | ||
-5.47% | 4.27B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- CLHO Stock
- Ratings Cleopatra Hospitals Group S.A.E.